The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation
The use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients. Unfortunately, conventional therapeutic strategy for relapsed/refractory disease is not acc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-01-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849409386316824576 |
|---|---|
| author | T. T. Valiev A. A. Khachatryan S. V. Goryacheva N. A. Batmanova K. I. Kirgizov S. R. Varfolomeeva |
| author_facet | T. T. Valiev A. A. Khachatryan S. V. Goryacheva N. A. Batmanova K. I. Kirgizov S. R. Varfolomeeva |
| author_sort | T. T. Valiev |
| collection | DOAJ |
| description | The use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients. Unfortunately, conventional therapeutic strategy for relapsed/refractory disease is not accepted, and the effectiveness of carboplat‑in- and gemcitabine-containing regimens is unsatisfactory. Clinical experience of rituximab, ibrutinib and nivolumab in combination with polychemotherapy and own clinical case of successful relapsed Burkitt lymphoma treatment with targeted therapy and following autologous and allogeneic hematopoietic stem cell transplantation are presented. Proposed program could achieve a complete remission of Burkitt lymphoma, but short-term after allogeneic hematopoietic stem cell transplantation diagnosed T-cell precursor acute lymphoblastic leukemia became fatal for the patient. |
| format | Article |
| id | doaj-art-3c78d79e364b4d8d9aebc4aac47983aa |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2024-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-3c78d79e364b4d8d9aebc4aac47983aa2025-08-20T03:35:32ZrusABV-pressОнкогематология1818-83462413-40232024-01-01191405010.17650/1818-8346-2024-19-1-40-50738The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantationT. T. Valiev0A. A. Khachatryan1S. V. Goryacheva2N. A. Batmanova3K. I. Kirgizov4S. R. Varfolomeeva5Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaThe use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients. Unfortunately, conventional therapeutic strategy for relapsed/refractory disease is not accepted, and the effectiveness of carboplat‑in- and gemcitabine-containing regimens is unsatisfactory. Clinical experience of rituximab, ibrutinib and nivolumab in combination with polychemotherapy and own clinical case of successful relapsed Burkitt lymphoma treatment with targeted therapy and following autologous and allogeneic hematopoietic stem cell transplantation are presented. Proposed program could achieve a complete remission of Burkitt lymphoma, but short-term after allogeneic hematopoietic stem cell transplantation diagnosed T-cell precursor acute lymphoblastic leukemia became fatal for the patient.https://oncohematology.abvpress.ru/ongm/article/view/896burkitt lymphomahematopoietic stem cell transplantationrelapsesecond-line therapytargeted therapy |
| spellingShingle | T. T. Valiev A. A. Khachatryan S. V. Goryacheva N. A. Batmanova K. I. Kirgizov S. R. Varfolomeeva The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation Онкогематология burkitt lymphoma hematopoietic stem cell transplantation relapse second-line therapy targeted therapy |
| title | The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation |
| title_full | The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation |
| title_fullStr | The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation |
| title_full_unstemmed | The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation |
| title_short | The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation |
| title_sort | experience of relapsed burkitt lymphoma treatment with targeted drugs and autologous allogeneic stem cell transplantation |
| topic | burkitt lymphoma hematopoietic stem cell transplantation relapse second-line therapy targeted therapy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/896 |
| work_keys_str_mv | AT ttvaliev theexperienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT aakhachatryan theexperienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT svgoryacheva theexperienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT nabatmanova theexperienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT kikirgizov theexperienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT srvarfolomeeva theexperienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT ttvaliev experienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT aakhachatryan experienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT svgoryacheva experienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT nabatmanova experienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT kikirgizov experienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation AT srvarfolomeeva experienceofrelapsedburkittlymphomatreatmentwithtargeteddrugsandautologousallogeneicstemcelltransplantation |